In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent oral bisphosphonate-related osteonecrosis.
The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide.
Autor: Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C.
